Skip to main content
CGTX logo

Cognition Therapeutics, Inc.

CGTXNASDAQHealthcareBiotechnology

$0.73Today:- (-)1Y −57.90%

As of Oct 16, 2026 close

Market cap
$66.39M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.55$2.00
Volume (live)
-
Avg. volume (3M)
534.29K

Cognition Therapeutics (CGTX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Cognition Therapeutics used $24.59M of cash in operating activities. Free cash flow was −$24.59M.

Cognition Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Cognition Therapeutics, Inc. (CGTX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-23.49-33.97-25.79-21.40-11.72-7.84-4.84
Depreciation & Amortization0.230.270.250.240.090.100.08
Deferred Income Tax0.000.000.000.000.000.000.24
Stock Based Compensation2.093.754.353.575.180.480.00
Change in Working Capital-3.461.294.85-0.942.843.070.57
Change in Accounts Receivable-7.24-1.412.39-1.41-1.110.90-1.12
Change in Inventory0.000.000.000.000.000.001.12
Change in Accounts Payable3.511.852.44-0.752.17-0.360.86
Change in Other Working Capital0.270.840.021.211.792.53-0.29
Other Operating Activities0.040.200.320.00-0.03-0.070.85
Net Cash from Operating Activities-24.59-28.47-16.02-18.53-3.63-3.43-3.10
Investing Activities
Capital Expenditures0.000.00-0.15-0.17-0.03-0.01-0.14
Acquisitions0.010.000.000.000.000.000.00
Net Cash from Investing Activities0.010.00-0.15-0.17-0.03-0.01-0.14
Financing Activities
Debt Repayment-0.35-0.74-0.81-1.40-0.270.002.83
Common Stock Issued37.0224.435.136.9444.220.050.00
Common Stock Repurchased0.00-0.130.000.000.000.000.00
Other Financing Activities-0.16-1.330.211.629.25-0.09-0.03
Net Cash from Financing Activities36.5723.574.525.5553.205.772.79
Summary
Effect of Forex Changes on Cash0.000.000.000.00-0.01-0.02-0.06
Net Change in Cash11.99-4.91-11.64-13.1649.532.30-0.51
Cash at Beginning of Period25.0129.9241.5654.725.192.893.40
Cash at End of Period37.0025.0129.9241.5654.725.192.89
Free Cash Flow-24.59-28.48-16.17-18.70-3.66-3.44-3.24

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Cognition Therapeutics Cash Flow

What is Cognition Therapeutics's free cash flow?

Cognition Therapeutics had negative free cash flow of $24.59M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Cognition Therapeutics pay dividends or buy back shares?

Cognition Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition